IFNA1 and portal hypertension: Thus, the development of noninvasive methods to distinguish between patients who benefited from IFN-free therapy (i.e., resolved liver fibrosis and portal hypertension) and patients who remain at a considerable risk for liver-related events is of high clinical relevance.